Iohexol

Generic Name: Iohexol

Brand Names: Omnipaque, Oraltag

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₆I_₃N_₃O_₉

CAS Number: 66108-95-0

Unique Ingredient Identifier: 4419T9MX03

Background: Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Indication: Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

Phase 4

Not yet recruiting

Conditions: Bacterial Infection

Interventions: Drug: Iohexol

First Posted Date: 2024-11-29

Last Posted Date: 2024-12-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 150

Registration Number: NCT06709521

Locations: 🇺🇸
Torrance Memorial Medical Center, Torrance, California, United States
🇺🇸
Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States
🇺🇸
Henry Ford Health System - Henry Ford Hospital, Detroit, Michigan, United States

and more 3 locations

Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate

Not Applicable

Not yet recruiting

Conditions: Chronic Kidney Diseases
Kidney Function Issue
Diagnosis

Interventions: Drug: Iohexol
Diagnostic Test: 125I-iothalamate and 131I-hippuran

First Posted Date: 2024-02-14

Last Posted Date: 2024-03-13

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 208

Registration Number: NCT06259422

Locations: 🇳🇱
University Medical Centre Groningen, Groningen, Netherlands

Ultrasound-guided LMBB by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method

Not Applicable

Recruiting

Conditions: Chronic Low-back Pain
Lumbar Facet Joint Syndrome

Interventions: Diagnostic Test: Lumbar medial branch block
Drug: Lidocain
Drug: Methylprednisolone
Drug: Omnipaque

First Posted Date: 2023-07-05

Last Posted Date: 2023-07-05

Lead Sponsor: Erasme University Hospital

Target Recruit Count: 40

Registration Number: NCT05930236

Locations: 🇧🇪
Hôpital Erasme, Bruxelles, Belgium

A Study of Effect of LY3556050 on Metformin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3556050
Drug: Metformin
Drug: Iohexol

First Posted Date: 2022-11-14

Last Posted Date: 2023-01-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT05615467

Locations: 🇺🇸
PRA International, Salt Lake City, Utah, United States

A Study of LY3526318 in Healthy Male Japanese Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: LY3526318
Drug: Placebo
Drug: Iohexol
Drug: Simvastatin
Drug: Metformin

First Posted Date: 2022-10-14

Last Posted Date: 2023-01-09

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT05580250

Locations: 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan

Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance

Phase 1

Not yet recruiting

Conditions: Kidney Function Test

Interventions: Drug: Iohexol
Biological: pharmacokinetics

First Posted Date: 2021-11-30

Last Posted Date: 2024-04-29

Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Target Recruit Count: 48

Registration Number: NCT05136963

Locations: 🇫🇷
Centre Hospitalier Universitaire, Saint-Étienne, France

Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function

Phase 1

Completed

Conditions: Chronic Kidney Failure

Interventions: Drug: Furosemide Injection
Drug: Creatinine Powder
Drug: Iohexol

First Posted Date: 2021-11-03

Last Posted Date: 2024-12-17

Lead Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez

Target Recruit Count: 50

Registration Number: NCT05105009

Locations: 🇲🇽
Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

Phase 4

Conditions: Contrast Media Reaction
Coronary Artery Disease

Interventions: Drug: Iodixanol
Drug: Iohexol

First Posted Date: 2021-10-01

Last Posted Date: 2021-10-25

Lead Sponsor: Minneapolis Heart Institute Foundation

Target Recruit Count: 62

Registration Number: NCT05065073

Locations: 🇺🇸
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States

Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance

Not Applicable

Recruiting

Conditions: Augmented Renal Clearance
Critically Ill

Interventions: Drug: Iohexol

First Posted Date: 2021-03-01

Last Posted Date: 2024-01-03

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 90

Registration Number: NCT04776486

Locations: 🇫🇷
Lariboisière Hospital, Surgical ICU, Paris, Ile De France, France

Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients

Phase 4

Completed

Conditions: Transgender
Renal Function
Hormone Replacement Therapy

Interventions: Diagnostic Test: IHX-CL measurements
Drug: Iohexol

First Posted Date: 2021-02-08

Last Posted Date: 2022-03-03

Lead Sponsor: University of California, San Diego

Target Recruit Count: 42

Registration Number: NCT04742816

Locations: 🇺🇸
UC San Diego AntiViral Research Center (AVRC), San Diego, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy